Dimerix Announces Expiry of Listed Options

Dimerix Limited ( (AU:DXB) ) has provided an update.

Dimerix Limited has announced the upcoming expiry of its listed options (ASX:DXBO), which are exercisable at $0.154 until June 30, 2025. The company has sent notifications to option holders, and trading of these options will cease on June 24, 2025. This announcement is significant as it impacts stakeholders holding these options and reflects the company’s ongoing financial management strategies.

The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.36 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.

More about Dimerix Limited

Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases, including kidney diseases. The company is advancing its proprietary Phase 3 product candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and DMX-700 for respiratory disease. Dimerix utilizes its proprietary Receptor Heteromer Investigation Technology (Receptor-HIT) to identify new drug opportunities.

Average Trading Volume: 3,262,328

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$355.1M

See more insights into DXB stock on TipRanks’ Stock Analysis page.